Men with untreated hypogonadism are at high risk of developing anaemia, sarcopaenia and osteoporosis 1 . Ageing males are likewise at increased risk of developing these conditions, so given the age-related decline in serum testosterone (T) concentrations observed in several population-based studies, there has long been an interest in a possible role for testosterone in ameliorating male frailty of old age (FoOA). Although interesting data are emerging from "The T trials" in relation to older men with obesity/metabolic syndrome, the overall evidence of benefit versus safety does not currently favour testosterone use for undifferentiated FoOA in routine clinical practice. This article is protected by copyright. All rights reserved.
Clinical endocrinology. 2018 Jul 10 [Epub ahead of print]
Ahmed Al-Sharefi, Richard Quinton
The Royal Victoria Infirmary, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK.